^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AMG 305

    i
    Other names: AMG 305, AMG305, AMG-305
    Associations

    News

    Trials
    Company:
    Amgen
    Drug class:
    CD3 agonist, Mesothelin inhibitor, CDH3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    28d
    Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=37, Active, not recruiting, Amgen | N=220 --> 37 | Trial completion date: Feb 2028 --> Apr 2026 | Trial primary completion date: Jun 2027 --> Apr 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    MSLN (Mesothelin) • CDH3 (Cadherin 3)
    |
    AMG 305
    11ms
    Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=220, Recruiting, Amgen | Trial completion date: Sep 2027 --> Feb 2028 | Trial primary completion date: Jan 2027 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    MSLN (Mesothelin) • CDH3 (Cadherin 3)
    |
    AMG 305
    over1year
    Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=260, Recruiting, Amgen | Trial completion date: Jan 2027 --> Aug 2027 | Trial primary completion date: May 2026 --> Dec 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    MSLN (Mesothelin) • CDH3 (Cadherin 3)
    |
    AMG 305
    almost2years
    Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=260, Recruiting, Amgen | Trial completion date: Oct 2026 --> Jan 2027 | Trial primary completion date: Feb 2026 --> May 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    MSLN (Mesothelin) • CDH3 (Cadherin 3)
    |
    AMG 305
    almost2years
    Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=260, Recruiting, Amgen | Trial primary completion date: Apr 2025 --> Feb 2026
    Trial primary completion date • Metastases
    |
    MSLN (Mesothelin) • CDH3 (Cadherin 3)
    |
    AMG 305
    over2years
    Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=260, Recruiting, Amgen | Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2026 --> Apr 2025
    Enrollment open • Trial primary completion date • Metastases
    |
    MSLN (Mesothelin) • CDH3 (Cadherin 3)
    |
    AMG 305
    almost3years
    Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=260, Not yet recruiting, Amgen
    New P1 trial • Metastases
    |
    MSLN (Mesothelin) • CDH3 (Cadherin 3)
    |
    AMG 305